About Nick Lagunowich

I lead an agile team of colleagues who are dedicated to driving innovation that prevents, diagnoses and treats the most prevalent health challenges facing society today.

As our society ages and changes in lifestyle accelerate the rate of obesity, we are facing a rising tide of metabolic risk that threatens both patients and healthcare systems. By 2030, over 1 billion people will be impacted by obesity, which is linked to over 200 comorbidities including type 2 diabetes, non-alcoholic steatohepatitis (NASH) and cardiovascular disease – the leading cause of death worldwide. My team and I come to work every day filled with ideas, resolve and passion to help address these challenges.

Over the past 24 years at Pfizer, I have held multiple leadership positions, including President of Rare Disease in North America, President of Internal Medicine in North America and General Manager and Business Unit Lead of our Essential Health business in Australia and New Zealand.

With a leading portfolio of innovative medicines and cutting-edge science, I am confident that Pfizer Internal Medicine can make a profound impact on the lives of patients, healthcare systems and society.